Groups Urge Congress to Act on Antibiotic Resistance

Pew and 25 other organizations call for incentives to spur new drug development

Groups Urge Congress to Act on Antibiotic Resistance

In a letter to congressional leaders Feb. 5, The Pew Charitable Trusts, Infectious Diseases Society of America, and Trust for America’s Health, together with U.S. antibiotic developers large and small, called on Congress to move swiftly to enact a package of economic incentives to reinvigorate the stagnant pipeline of antibiotics. The letter laid out key principles for a set of policies to ensure that the unique challenges of antibiotic development are addressed with solutions that are aligned with appropriate stewardship and surveillance.

Of the antibiotics in development today, only 11 have the potential to address Gram-negative bacteria, the so-called superbugs deemed most dangerous by the World Health Organization. Based on historical trends, perhaps just two of those drugs will ever make it to market. Despite this urgent need for new antibiotics, the future of antibiotic development is grim. Nearly all large pharmaceutical companies have discontinued their antibiotic research and development programs, and the remaining small biotech firms struggle to raise private funds. Without additional action, the market will not deliver the new antibiotics that patients need.

The 26 signees were:

  • Achaogen
  • Antimicrobial Innovation Alliance
  • Antimicrobials Working Group (Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc., ContraFect Corp., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma Inc., Scynexis Inc., Summit Therapeutics PLC, and VenatoRx Pharmaceuticals Inc.)
  • Biotechnology Innovation Organization
  • GlaxoSmithKline
  • Infectious Diseases Society of America
  • Merck
  • Pfizer Inc.
  • Shionogi Inc.
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals
  • The Pew Charitable Trusts
  • Trust for America’s Health

National Homeownership Month

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.